67.00Open67.00Pre Close0 Volume12 Open Interest210.00Strike Price0.00Turnover47.87%IV13.11%PremiumDec 20, 2024Expiry Date34.89Intrinsic Value100Multiplier27DDays to Expiry32.11Extrinsic Value100Contract SizeAmericanOptions Type0.8965Delta0.0056Gamma6.57Leverage Ratio-0.1268Theta0.1369Rho5.89Eff Leverage0.1207Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet